AIM
LYEL icon

Aigen Investment Management’s Lyell Immunopharma LYEL Stock Holding History

Aigen Investment Management’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-949
Closed -$26.2K – 886
2024
Q3 		$26.2K Buy
949
+54
+6% +$1.59K 0.01% 686
2024
Q2 		$26K Buy
+895
New +$42.6K 0.01% 733
2024
Q1 		– Sell
-763
Closed -$29.6K – 879
2023
Q4 		$29.6K Buy
763
+60
+9% +$2.16K 0.01% 755
2023
Q3 		$20.7K Buy
+703
New +$33.4K ﹤0.01% 783

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

Aigen Investment Management's LYEL Position: Q4 2024 in Review

Aigen Investment Management sold out of Lyell Immunopharma (LYEL) in Q4 2024, closing a stake of 949 shares — an estimated $26.2K sold.

Aigen Investment Management first reported a position in LYEL in Q3 2023 and held it in 4 quarters. The position peaked at $29.6K in Q4 2023. 105 funds tracked by Wall St. Rank hold LYEL as of Q4 2024.

  • Aigen Investment Management reported no remaining Lyell Immunopharma position as of Q4 2024 after selling out during the quarter.
  • Aigen Investment Management sold 949 Lyell Immunopharma shares in Q4 2024, an estimated $26.2K.
  • Aigen Investment Management first reported a position in Lyell Immunopharma in Q3 2023 and held it in 4 quarters.
  • Aigen Investment Management's Lyell Immunopharma position peaked at $29.6K in Q4 2023.
  • 105 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q4 2024.

Based on Aigen Investment Management's 13F filing for Q4 2024, filed 6 Feb 2025.